#sun pharma

2 stories

#biocon #bridge loan #business #debt sale #drug development #glenmark pharma #india #indian pharma #innovation #money #ncd issue #organon co

Indian Pharma Risk Aversion
Indian pharma leaders say risk aversion blocks innovation, urging tech adoption for faster drug development.
The Economic Times · 1m
Sun Pharma to consider ₹15,000 crore NCD issue
Sun Pharma plans ₹15,000 crore debt sale to fund Organon acquisition bridge loan.
mint · 1m